ciprofloxacin has been researched along with Hematologic Neoplasms in 22 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Hematologic Neoplasms: Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a single-center open-label prospective study, a total of 134 marrow transplant recipients with hematologic malignancies were randomly assigned to a bacterial decontamination medication using metronidazole and ciprofloxacin (n = 68) or ciprofloxacin alone (n = 66) during 5 weeks posttransplant." | 9.09 | Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and ( Beelen, DW; Elmaagacli, A; Hirche, H; Müller, KD; Schaefer, UW, 1999) |
| "We investigate ciprofloxacin pharmacokinetics after oral administration in patients with haematological malignancies and explore the impact of GI-mucositis on oral bioavailability and clearance in order to assure adequate systemic exposure." | 8.12 | Impact of mucositis on oral bioavailability and systemic exposure of ciprofloxacin Gram-negative infection prophylaxis in patients with haematological malignancies. ( Blijlevens, NMA; Bruggemann, RJM; de Vroom, SL; Geerlings, SE; Knibbe, CAJ; Mathôt, RAA; Molendijk, E; Tonino, SH; van der Linden, PD; van Hest, RM; van Rhee, KP, 2022) |
| " Ciprofloxacin prophylaxis appears safe and effective in reducing the incidence of severe BKHC after allogeneic HSCT." | 5.37 | Efficacy and safety of ciprofloxacin for prophylaxis of polyomavirus BK virus-associated hemorrhagic cystitis in allogeneic hematopoietic stem cell transplantation recipients. ( Costa, LJ; Glode, A; Hogan, KR; Kramer, C; Miller, AN; Schaub, C; Stuart, RK, 2011) |
| "Ciprofloxacin (CPFX) is a potential alternative in patients with febrile neutropenia (FN) because of its activity against Gram-negative organisms." | 5.17 | Randomized controlled trial comparing ciprofloxacin and cefepime in febrile neutropenic patients with hematological malignancies. ( Atsuta, Y; Emi, N; Inamoto, Y; Ishikawa, Y; Nagai, H; Naoe, T; Ozawa, Y; Ozeki, K; Suzuki, R; Terakura, S; Yanada, M; Yasuda, T, 2013) |
| " After a pre-intervention period, in which cefepime was used as the initial agent for febrile neutropenia, 4 primary antibiotics, namely, piperacillin-tazobactam, ciprofloxacin, meropenem, and cefepime, were rotated at 1-month intervals over 20 months." | 5.17 | Antibiotic rotation for febrile neutropenic patients with hematological malignancies: clinical significance of antibiotic heterogeneity. ( Akashi, K; Chong, Y; Ito, Y; Kamimura, T; Miyamoto, T; Shimoda, S; Shimono, N; Yakushiji, H, 2013) |
| "An open-label randomised clinical trial was designed to compare the efficacy and tolerance of levofloxacin and ciprofloxacin plus phenethicillin for the prevention of bacterial infections in patients with high-risk neutropenia, and to monitor the emergence of antimicrobial resistance." | 5.12 | Levofloxacin vs. ciprofloxacin plus phenethicillin for the prevention of bacterial infections in patients with haematological malignancies. ( Huijgens, PC; Janssen, JJ; Leidekker, ME; Simoons-Smit, AM; Timmers, GJ; Vandenbroucke-Grauls, CM, 2007) |
| "In a single-center open-label prospective study, a total of 134 marrow transplant recipients with hematologic malignancies were randomly assigned to a bacterial decontamination medication using metronidazole and ciprofloxacin (n = 68) or ciprofloxacin alone (n = 66) during 5 weeks posttransplant." | 5.09 | Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and ( Beelen, DW; Elmaagacli, A; Hirche, H; Müller, KD; Schaefer, UW, 1999) |
| "The objective of this study was to characterize the prevalence and clinical significance of ciprofloxacin-resistant Escherichia coli in perianal swabs of patients with hematologic malignancies in a German university hospital." | 5.09 | Prevalence of ciprofloxacin-resistant Escherichia coli in hematologic-oncologic patients. ( Baum, HV; Franz, U; Geiss, HK, 2000) |
| "We investigate ciprofloxacin pharmacokinetics after oral administration in patients with haematological malignancies and explore the impact of GI-mucositis on oral bioavailability and clearance in order to assure adequate systemic exposure." | 4.12 | Impact of mucositis on oral bioavailability and systemic exposure of ciprofloxacin Gram-negative infection prophylaxis in patients with haematological malignancies. ( Blijlevens, NMA; Bruggemann, RJM; de Vroom, SL; Geerlings, SE; Knibbe, CAJ; Mathôt, RAA; Molendijk, E; Tonino, SH; van der Linden, PD; van Hest, RM; van Rhee, KP, 2022) |
| " We evaluated retrospectively the effect of antibiotic prophylaxis with ciprofloxacin and penicillin on the prevention of bacterial infections in 112 cases of prolonged neutropenia in adult patients treated for haematological malignancies." | 3.70 | [Evaluation of antibiotic prophylaxis in neutropenic patients with hematologic malignancies]. ( Baumgartner, JD; Cometta, A; Delarive, P; Glauser, MP, 2000) |
| "aeruginosa isolates from children with hematologic malignancies containing bacterial persisters that cause the AT phenomenon." | 2.82 | [Generation of Antibiotic Tolerant Bacterial Persisters in Immunocompromized Patients with Hematologic and Malignant Diseases: A New Problem of Health-Care Associated Infections]. ( Gaponov, AM; Gracheva, AN; Minaeva, NZ; Pisarev, VM; Solopova, GG; Tutelyan, AV, 2016) |
| " Ciprofloxacin prophylaxis appears safe and effective in reducing the incidence of severe BKHC after allogeneic HSCT." | 1.37 | Efficacy and safety of ciprofloxacin for prophylaxis of polyomavirus BK virus-associated hemorrhagic cystitis in allogeneic hematopoietic stem cell transplantation recipients. ( Costa, LJ; Glode, A; Hogan, KR; Kramer, C; Miller, AN; Schaub, C; Stuart, RK, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (22.73) | 18.2507 |
| 2000's | 6 (27.27) | 29.6817 |
| 2010's | 8 (36.36) | 24.3611 |
| 2020's | 3 (13.64) | 2.80 |
| Authors | Studies |
|---|---|
| van Rhee, KP | 1 |
| de Vroom, SL | 1 |
| van Hest, RM | 1 |
| van der Linden, PD | 1 |
| Tonino, SH | 1 |
| Molendijk, E | 1 |
| Mathôt, RAA | 1 |
| Blijlevens, NMA | 1 |
| Knibbe, CAJ | 1 |
| Bruggemann, RJM | 1 |
| Geerlings, SE | 1 |
| Oliver, AC | 1 |
| Riva, E | 1 |
| Mosquera, R | 1 |
| Galeano, S | 1 |
| Pierri, S | 1 |
| Bello, L | 1 |
| Caneiro, A | 1 |
| Gai, R | 1 |
| Miller, A | 1 |
| Muxi, P | 1 |
| Valcarcel, B | 1 |
| De-la-Cruz-Ku, G | 1 |
| Malpica, L | 1 |
| Enriquez-Vera, D | 1 |
| Conn, JR | 1 |
| Catchpoole, EM | 1 |
| Runnegar, N | 1 |
| Mapp, SJ | 1 |
| Markey, KA | 1 |
| Tutelyan, AV | 1 |
| Pisarev, VM | 1 |
| Minaeva, NZ | 1 |
| Gaponov, AM | 1 |
| Gracheva, AN | 1 |
| Solopova, GG | 1 |
| Eleutherakis-Papaiakovou, E | 1 |
| Kostis, E | 1 |
| Migkou, M | 1 |
| Christoulas, D | 1 |
| Terpos, E | 1 |
| Gavriatopoulou, M | 1 |
| Roussou, M | 1 |
| Bournakis, E | 1 |
| Kastritis, E | 1 |
| Efstathiou, E | 1 |
| Dimopoulos, MA | 1 |
| Papadimitriou, CA | 1 |
| Miller, AN | 1 |
| Glode, A | 1 |
| Hogan, KR | 1 |
| Schaub, C | 1 |
| Kramer, C | 1 |
| Stuart, RK | 1 |
| Costa, LJ | 1 |
| van Hees, BC | 1 |
| Tersmette, M | 1 |
| Willems, RJ | 1 |
| de Jong, B | 1 |
| Biesma, D | 1 |
| van Hannen, EJ | 1 |
| Yasuda, T | 1 |
| Suzuki, R | 1 |
| Ishikawa, Y | 1 |
| Terakura, S | 1 |
| Inamoto, Y | 1 |
| Yanada, M | 1 |
| Nagai, H | 1 |
| Ozawa, Y | 1 |
| Ozeki, K | 1 |
| Atsuta, Y | 1 |
| Emi, N | 1 |
| Naoe, T | 1 |
| Chong, Y | 1 |
| Shimoda, S | 1 |
| Yakushiji, H | 1 |
| Ito, Y | 1 |
| Miyamoto, T | 1 |
| Kamimura, T | 1 |
| Shimono, N | 1 |
| Akashi, K | 1 |
| Schelenz, S | 1 |
| Nwaka, D | 1 |
| Hunter, PR | 1 |
| Cometta, A | 2 |
| Kern, W | 1 |
| Rókusz, L | 1 |
| László, L | 1 |
| Timmers, GJ | 1 |
| Simoons-Smit, AM | 1 |
| Leidekker, ME | 1 |
| Janssen, JJ | 1 |
| Vandenbroucke-Grauls, CM | 1 |
| Huijgens, PC | 1 |
| Marie, JP | 1 |
| Vekhoff, A | 1 |
| Pico, JL | 1 |
| Guy, H | 1 |
| Andremont, A | 1 |
| Richet, H | 1 |
| Nouwen, JL | 1 |
| van Belkum, A | 1 |
| de Marie, S | 1 |
| Sluijs, J | 1 |
| Wielenga, JJ | 1 |
| Kluytmans, JA | 1 |
| Verbrugh, HA | 1 |
| van Kraaij, MG | 1 |
| Dekker, AW | 1 |
| Peters, E | 1 |
| Fluit, A | 1 |
| Verdonck, LF | 1 |
| Rozenberg-Arska, M | 1 |
| Kerr, KG | 1 |
| Armitage, HT | 1 |
| McWhinney, PH | 1 |
| Beelen, DW | 2 |
| Elmaagacli, A | 2 |
| Müller, KD | 2 |
| Hirche, H | 1 |
| Schaefer, UW | 2 |
| Baum, HV | 1 |
| Franz, U | 1 |
| Geiss, HK | 1 |
| Trenschel, R | 1 |
| Peceny, R | 1 |
| Runde, V | 1 |
| Dermoumi, H | 1 |
| Heintschel von Heinegg, E | 1 |
| Delarive, P | 1 |
| Baumgartner, JD | 1 |
| Glauser, MP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Ciprofloxacin for Prevention of BK Infection in Renal Transplant Recipients[NCT01789203] | Phase 4 | 200 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| Randomized Controlled Trial Comparing Ciprofloxacin With Cefepime in Febrile Neutropenic Patients With Hematologic Diseases[NCT00137787] | Phase 3 | 51 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of patients with biopsy-proven acute rejection of the allograft at 1 year, based on Banff classification (NCT01789203)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 14 |
| Placebo | 7 |
Proportion of patients developing BK viremia at 1 year (NCT01789203)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 31 |
| Placebo | 8 |
Clostridium difficile infection at 6 months (NCT01789203)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 1 |
| Placebo | 0 |
Patient death at 1 year (NCT01789203)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 1 |
| Placebo | 1 |
First BK plasma viral loads (NCT01789203)
Timeframe: 12 months
| Intervention | copies/mL (Median) |
|---|---|
| Ciprofloxacin | 2514 |
| Placebo | 1423 |
kidney failure within first 1 year of transplant (NCT01789203)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 14 |
| Placebo | 7 |
Number of patients (followed by proportion) developing BK infection at 6 months post-transplant. BK infection is defined as the presence of a detectable BK viral load in plasma by polymerase chain reaction (PCR), or the presence of BK viral inclusions on kidney biopsy specimens. (NCT01789203)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 25 |
| Placebo | 5 |
Number of patients with bacteremic infection at 6 months. Bacteremia defined by a single positive blood culture that was not thought to be contaminated. (NCT01789203)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 3 |
| Placebo | 2 |
Number of patients with gram negative urinary tract infections as defined by a midstream urine sample containing 10^4 or more colony-forming units per mL (NCT01789203)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 17 |
| Placebo | 14 |
Number of patients with quinolone-resistant gram negative bacterial infections, among those with a gram-negative infection (NCT01789203)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 15 |
| Placebo | 7 |
Serious adverse events collected for up to 4 months (3 months on study drug plus 1 additional month) (NCT01789203)
Timeframe: 4 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 35 |
| Placebo | 18 |
Median time to initial BK viremia episode, days (NCT01789203)
Timeframe: 12 months
| Intervention | days (Median) |
|---|---|
| Ciprofloxacin | 90 |
| Placebo | 76.5 |
1 review available for ciprofloxacin and Hematologic Neoplasms
| Article | Year |
|---|---|
[Treatment with oral antibiotics of febrile neutropenia in onco-haematology. The experience of the EORTC antimicrobial group].
Topics: Administration, Oral; Amoxicillin-Potassium Clavulanate Combination; Bacterial Infections; Ceftazidi | 2004 |
10 trials available for ciprofloxacin and Hematologic Neoplasms
| Article | Year |
|---|---|
Low rates of antibiotic resistance and infectious mortality in a cohort of high-risk hematology patients: A single center, retrospective analysis of blood stream infection.
Topics: Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Drug Resistance, Bacterial; Febrile Neutropenia; F | 2017 |
[Generation of Antibiotic Tolerant Bacterial Persisters in Immunocompromized Patients with Hematologic and Malignant Diseases: A New Problem of Health-Care Associated Infections].
Topics: Adolescent; Anti-Bacterial Agents; Child; Ciprofloxacin; Cross Infection; Drug Resistance, Microbial | 2016 |
Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem-cell transplantation: results of a single institution, randomized phase 2 trial.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Ciprofloxacin; Fever; Graft Survival; Hematologic Neo | 2010 |
Randomized controlled trial comparing ciprofloxacin and cefepime in febrile neutropenic patients with hematological malignancies.
Topics: Adolescent; Adult; Aged; Algorithms; Anti-Bacterial Agents; Cefepime; Cephalosporins; Ciprofloxacin; | 2013 |
Antibiotic rotation for febrile neutropenic patients with hematological malignancies: clinical significance of antibiotic heterogeneity.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactam Resistance; Cefepime; | 2013 |
Levofloxacin vs. ciprofloxacin plus phenethicillin for the prevention of bacterial infections in patients with haematological malignancies.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Ciprofloxacin; Cross Infecti | 2007 |
Neutropenic infections: a review of the French Febrile Aplasia Study Group trials in 608 febrile neutropenic patients.
Topics: Amikacin; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Ciprofloxacin; Drug Therapy, Combinati | 1998 |
Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and
Topics: Adolescent; Adult; Anti-Bacterial Agents; Bone Marrow Transplantation; Ciprofloxacin; Drug Therapy, | 1999 |
Prevalence of ciprofloxacin-resistant Escherichia coli in hematologic-oncologic patients.
Topics: Anti-Infective Agents; Bacteremia; Bacterial Infections; Ciprofloxacin; Drug Resistance, Microbial; | 2000 |
Fungal colonization and invasive fungal infections following allogeneic BMT using metronidazole, ciprofloxacin and fluconazole or ciprofloxacin and fluconazole as intestinal decontamination.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antifungal Agents; Aspergillosis; | 2000 |
11 other studies available for ciprofloxacin and Hematologic Neoplasms
| Article | Year |
|---|---|
Impact of mucositis on oral bioavailability and systemic exposure of ciprofloxacin Gram-negative infection prophylaxis in patients with haematological malignancies.
Topics: Administration, Oral; Adult; Biological Availability; Ciprofloxacin; Citrulline; Hematologic Neoplas | 2022 |
Comparison of two different anti-infectious approaches after high-dose chemotherapy and autologous stem cell transplantation for hematologic malignancies in a 12-year period in British Hospital, Uruguay.
Topics: Adolescent; Adult; Aged; Amikacin; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Prot | 2020 |
Clinical features and outcome of Aeromonas sobria bacteremia in pediatric and adult patients with hematologic malignancies: A single-center retrospective study in Peru.
Topics: Adolescent; Adult; Aeromonas; Aged; Bacteremia; Child; Child, Preschool; Ciprofloxacin; Cross Infect | 2021 |
Efficacy and safety of ciprofloxacin for prophylaxis of polyomavirus BK virus-associated hemorrhagic cystitis in allogeneic hematopoietic stem cell transplantation recipients.
Topics: Adult; Aged; Anti-Infective Agents; BK Virus; Ciprofloxacin; Cystitis; Female; Hematologic Neoplasms | 2011 |
Molecular analysis of ciprofloxacin resistance and clonal relatedness of clinical Escherichia coli isolates from haematology patients receiving ciprofloxacin prophylaxis.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Ciprofloxacin; Cluster Analysis; Denaturing Gradient | 2011 |
Longitudinal surveillance of bacteraemia in haematology and oncology patients at a UK cancer centre and the impact of ciprofloxacin use on antimicrobial resistance.
Topics: Anti-Bacterial Agents; Bacteremia; Cancer Care Facilities; Ciprofloxacin; Drug Resistance, Bacterial | 2013 |
Infections of febrile neutropenic patients in malignant hematological diseases (second study period).
Topics: Antibiotic Prophylaxis; Antineoplastic Agents; Bacteremia; Bacterial Infections; Ciprofloxacin; Fema | 2005 |
Clonal expansion of Staphylococcus epidermidis strains causing Hickman catheter-related infections in a hemato-oncologic department.
Topics: Air Microbiology; Antibiotic Prophylaxis; Bacteriological Techniques; Catheterization, Central Venou | 1998 |
Emergence and infectious complications of ciprofloxacin-resistant Escherichia coli in haematological cancer patients.
Topics: Bone Marrow Transplantation; Ciprofloxacin; Drug Resistance, Microbial; Escherichia coli; Escherichi | 1998 |
Activity of quinolones against viridans group streptococci isolated from blood cultures of patients with haematological malignancy.
Topics: Adult; Anti-Infective Agents; Bacteremia; Ciprofloxacin; Fleroxacin; Fluoroquinolones; Hematologic N | 1999 |
[Evaluation of antibiotic prophylaxis in neutropenic patients with hematologic malignancies].
Topics: Adult; Aged; Antibiotic Prophylaxis; Antineoplastic Agents; Bacterial Infections; Ciprofloxacin; Dru | 2000 |